Results 41 to 50 of about 24,593 (224)
Validation of on‐slide immunocytochemistry controls prepared from long‐term preserved prefixed cell suspensions
Cancer Cytopathology, Volume 134, Issue 2, February 2026.Abstract Background
On‐slide controls are essential for quality assurance in immunocytochemistry, yet their use in non–cell block cytology preparations remains a significant challenge. This study presents and evaluates a novel method for preparing on‐slide controls from long‐term prefixed cell suspensions, applicable to all types of cytology ...Rúben Rodrigues Roque, Irena Srebotnik Kirbiš, Carla Sofia Castro Pinheiro, Rita Sattler Fagulha Martins, Vanessa Sofia Tavares, Saudade André, Ana Félix +6 morewiley +1 more sourceNew Quinoline Kinase Inhibitors With Good Selectivity for NAK Kinases and Anti‐Tumor Activity Against Ewing Sarcoma
Archiv der Pharmazie, Volume 359, Issue 1, January 2026.Focusing on the discovery of new therapeutics for childhood cancer, novel quinoline derivatives were synthesized and demonstrated activity against Ewing sarcoma. A target search was performed against a panel of kinases, and the compounds showed selectivity for the NAK family, mainly GAK, which was confirmed by enzyme kinetic assays.Caroline de Bem Gentz, Thais Helena Maciel Fernandes, Marcela Silva Lopes, Lewis Elson, Andreas Krämer, Lucas Rodrigo de Souza, Isadora Serraglio Fortes, Geórgia Silva Pinto, Martha Cestari Silva Martins, Henrique Barros de Lima, André da Silva Santiago, Lauro José Gregianin, Katlin Brauer Massirer, Mário Henrique Bengtson, Rafael Roesler, Stefan Knapp, Stefan A. Laufer, Saulo Fernandes de Andrade +17 morewiley +1 more sourceBlinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study
HemaSphere, Volume 10, Issue 1, January 2026.Abstract
Pediatric regimens improve outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. End‐consolidation (time point 2 [TP2]) minimal residual disease negativity (MRDneg) is associated with improved survival. In this study, standard consolidation chemotherapy was replaced with blinatumomab to improve TP2 MRDneg—a ...Matthew Greenwood, Shane Gangatharan, Michael Osborn, Ashley P. Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Jacqueline Rehn, Elyse Page, Susan Heatley, Peter Button, Leesa Rowley, Stephen R. Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla Pozza, David Yeung, Deborah White, the Australasian Leukaemia and Lymphoma Group +26 morewiley +1 more sourceTALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey
Hematological Oncology, Volume 44, Issue 1, January 2026.ABSTRACT
The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study.Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali, Piera Angelillo, Enrico Amaducci, Filippo Ballerini, Flaminia Bellisario, Andrea Bernardelli, Riccardo Bruna, Catello Califano, Giusy Cetani, Giulia Daghia, Enrico Derenzini, Antonio Frolli, Francesco Gaudio, Valerio Guarente, Ausilia Gorgone, Liardo Eliana Valentina, Elisa Lucchini, Dario Marino, Luca Nassi, Paolo Nicoli, Mattia Novo, Francesca Palombi, Caterina Patti, Vincenzo Pavone, Marcello Riva, Filomena Russo, Greta Scapinello, Alessandro Severino, Monica Tani, Daniele Vallisa, Beatrice Casadei, Alessandro Broccoli, Pier Luigi Zinzani +34 morewiley +1 more sourceNPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Hematological Oncology, Volume 44, Issue 1, January 2026.ABSTRACT
In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.Calogero Vetro, Irene Azzali, Elisabetta Petracci, Cristina Papayannidis, Eleonora Eleuteri, Fanny Erika Palumbo, Vincenzo Federico, Nicola Fracchiolla, Patrizia Zappasodi, Maria Paola Martelli, Maria Benedetta Giannini, Lorenzo Brunetti, Raffaele Palmieri, Jacopo Nanni, Giorgia Simonetti, Fabio Guolo, Paola Minetto, Luca Maurillo, Federica Gigli, Atto Billio, Elisabetta Todisco, Giovanni Martinelli, Giovanni Marconi +22 morewiley +1 more sourceGenetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
International Journal of Cancer, Volume 158, Issue 1, Page 45-59, 1 January 2026.What's new?
Obesity has been linked to the risk of non‐Hodgkin lymphoma (NHL), but the evidence remains inconclusive. Here, the authors investigate the possibility of shared genetic risk factors between obesity and four common NHL types. Drawing on data from 8 genome‐wide association studies, they found that a higher genetically determined BMI was ...Amy Moore, Eleanor Kane, Lauren R. Teras, Mitchell J. Machiela, Joshua Arias, Orestis A. Panagiotou, Alain Monnereau, Nicole Wong Doo, Zhaoming Wang, Susan L. Slager, Roel C. H. Vermeulen, Claire M. Vajdic, Karin E. Smedby, John J. Spinelli, Joseph Vijai, Graham G. Giles, Brian K. Link, Alan A. Arslan, Alexandra Nieters, Paige M. Bracci, Nicola J. Camp, Gilles Salles, Wendy Cozen, Henrik Hjalgrim, Immaculata De Vivo, Hans‐Olov Adami, Demetrius Albanes, Nikolaus Becker, Yolanda Benavente, Simonetta Bisanzi, Paolo Boffetta, Paul Brennan, Angela R. Brooks‐Wilson, Federico Canzian, Jacqueline Clavel, Lucia Conde, David G. Cox, Karen Curtin, Lenka Foretova, Hervé Ghesquières, Bengt Glimelius, Thomas M. Habermann, Jonathan N. Hofmann, Qing Lan, Mark Liebow, Anne Lincoln, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Lindsay M. Morton, Kari E. North, Kenneth Offit, Marina Padoan, Sara Piro, Alpa V. Patel, Mark P. Purdue, Vignesh Ravichandran, Elio Riboli, Richard K. Severson, Melissa C. Southey, Anthony Staines, Lesley F. Tinker, Ruth C. Travis, Sophia S. Wang, Elisabete Weiderpass, Stephanie Weinstein, Tongzhang Zheng, Stephen J. Chanock, Nathaniel Rothman, Brenda M. Birmann, James R. Cerhan, Sonja I. Berndt +74 morewiley +1 more sourceVenetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
British Journal of Haematology, EarlyView.Elisabetta Petracci, Francesca Pavesi, Luca Castagna, Patrizia Zappasodi, Cristina Papayannidis, Calogero Vetro, Vincenzo Federico, Alessandro Cignetti, Erika Borlenghi, Nicola Fracchiolla, Luca Facchini, Luca Maurillo, Ernesta Audisio, Massimo Bernardi, Felicetto Ferrara, Francesco Lanza, Carmine Selleri, Ilenia Manfra, Claudio Cerchione, Jacopo Nanni, Andrea Davide Romagnoli, Giovanni Marconi, Chiara Zingaretti, Ivana Lotesoriere, Federica Gigli, Giovanni Martinelli, Elisabetta Todisco +26 morewiley +1 more sourceGaps Between European Crohn's Colitis Organisation Quality Standards of Care and the Real World in Special Situations in Inflammatory Bowel Disease Across Europe: Results From E‐QUALITY Survey
JCC Plus, Volume 1, Issue 1, January 2026.ABSTRACT Background
Managing special situations in Inflammatory Bowel Disease (IBD)—such as surgery, nutrition, acute severe ulcerative colitis (ASUC) and paediatric‐to‐adult transition—is critical for patient outcomes. The European Crohn's and Colitis Organisation's (ECCO) E‐QUALITY initiative aimed to identify gaps between its evidence‐based care ...Gionata Fiorino, Catarina Fidalgo, Michel Adamina, Manuel Barreiro‐de Acosta, Mariam P. Ali, Martin Bortlik, Johan Burisch, Axel Dignass, David Drobne, Omar Faiz, Marc Ferrante, Liselotte Fierens, Lihi Godny, Anna Gojdicova, Marietta Iacucci, Susanna Jӓghult, Konstantinos Karmiris, Julien Kirchgesner, Sophie Restellini, Francesca Rosini, Dror Shouval, Henit Yanai, Edyta Zagórowicz, Alissa Walsh, on behalf of European Crohn's Colitis Organisation +24 morewiley +1 more sourceObesity as a Risk Factor for Autoimmune Diseases: A Systematic Review and Meta‐Analysis
Obesity, Volume 34, Issue 1, Page 36-50, January 2026.Summary of the meta‐analysis including 26 studies (8 cross‐sectional, 18 longitudinal) investigating the association between obesity and autoimmune diseases. Findings show increased prevalence and incidence of rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel diseases in people with obesity, suggesting that obesity may ...Ilaria Spatocco, Giorgia Mele, Giusy De Rosa, Clorinda Fusco, Kristyna Ruggiero, Valeria Pellegrini, Francesca Carreras, Rosalba La Grotta, Antonio Ceriello, Claudio Procaccini, Giuseppe Matarese, Francesco Prattichizzo, Paola de Candia +12 morewiley +1 more source
